<DOC>
	<DOC>NCT01034267</DOC>
	<brief_summary>The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.</brief_summary>
	<brief_title>Safety Study of F2695 SR in Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Completed 1 of the leadin studies LVMMD01, LVMMD02, or LVMMD03 Have normal examination findings at the final visit of the leadin study Have a negative serum pregnancy test at the final visit of the leadin study if a woman of childbearing potential Any exclusionary psychiatric or medical condition that developed during the lead in study Patients considered a suicide risk Women who are pregnant, breastfeeding, or planning to become during the study OR are sexually active and not currently using a medically acceptable method of contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>